Celldex Therapeutics, Inc. cash flow statement CLDX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Celldex Therapeutics, Inc. used $210.9 million of cash from operations, down 33.7% from the year before. It spent $2.7 million on capital expenditures. Free cash flow was negative, at -$213.7 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Operating
Depreciation and amortization	3 +1.5%	3 +6.4%	3 +5.6%	3 +3.9%	3 -5.6%	3 -21.9%	4 -19.1%	5 +35.8%	4 -19.0%	4 +42.6%	3 +3.2%
Stock-based compensation	35 -8.6%	36 +5.8%	34 +43.3%	24 +53.0%	16 +74.4%	9 +128.7%	4 -14.0%	5 -43.7%	8 -34.4%	12 -19.6%	15 +19.9%
Operating cash flow	-236 -26.5%	-211 -33.7%	-158 -47.1%	-107 -3.4%	-104 -70.3%	-61 -50.7%	-40 +13.0%	-46 +38.3%	-75 +24.7%	-100 +11.6%	-113 -14.3%
Investing
Capital expenditures	7 +185.0%	3 +41.4%	2 +5.6%	2 -0.5%	2 +46.4%	1 -19.5%	2 +112.3%	1 -10.1%	1 -54.5%	2 -35.0%	3 -43.6%
Investing cash flow	-67 -140.8%	209 +172.1%	-290 -174.3%	-106 -217.6%	90 +141.6%	-216 -120.1%	-98 -675.0%	17 -42.7%	30 -35.8%	46 -32.6%	69 +237.3%
Financing
Financing cash flow	327 +17207.2%	2 -99.5%	441 +102.1%	218 +5259.6%	4 -98.5%	272 +59.1%	171 +953.2%	16 -44.8%	29 -42.6%	51 +254.2%	14 -92.5%
Change in cash
Net change in cash	24 +223.9%	1 +108.0%	-6 -219.9%	5 +155.4%	-10 -107.0%	-5 -114.4%	33	—	—	—	—
Free cash flow	-242 -28.4%	-214 -33.8%	-160 -46.4%	-109 -3.4%	-106 -69.8%	-62 -48.2%	-42 +11.0%	-47 +38.0%	-76 +25.2%	-102 +12.1%	-116 -11.6%
Per share
Free cash flow per share	-3.49 -80.4%	-3.22 -29.7%	-2.48 -10.1%	-2.25 +99.9%	-2,251.32 -55.3%	-1,449.92	—	—	—	—	—
Ratios
Free cash flow margin	-153,231.01%	-13,829.06%	-2,274.89%	-1,585.20%	-4,478.57%	-1,336.44%	-565.60%	-1,319.51%	-797.32%	-798.23%	-1,706.26%
Capital expenditures to revenue	4,138.61%	175.66%	27.34%	26.41%	77.56%	26.85%	20.92%	20.46%	8.52%	14.03%	40.54%
Stock-based compensation to revenue	21,924.68%	2,344.14%	487.78%	347.09%	662.32%	192.50%	52.78%	127.37%	84.72%	96.62%	225.71%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: CLDX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Hampton, NJ
SEC filer status: Large accelerated filer
SEC CIK: 744218
Former names: AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.